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We have isolated and microsequenced Snu17p, a novel yeast protein with a predicted molecular mass of 17
kDa that contains an RNA recognition motif. We demonstrate that Snu17p binds specifically to the U2 small
nuclear ribonucleoprotein (snRNP) and that it is part of the spliceosome, since the pre-mRNA and the lariat-
exon 2 are specifically coprecipitated with Snu17p. Although the SNU17 gene is not essential, its knockout leads
to a slow-growth phenotype and to a pre-mRNA splicing defect in vivo. In addition, the first step of splicing is
dramatically decreased in extracts prepared from the snu17 deletion (snu17D) mutant. This defect is efficiently
reversed by the addition of recombinant Snu17p. To investigate the step of spliceosome assembly at which
Snu17p acts, we have used nondenaturing gel electrophoresis. In Snu17p-deficient extracts, the spliceosome
runs as a single slowly migrating complex. In wild-type extracts, usually at least two distinct complexes are
observed: the prespliceosome, or B complex, containing the U2 but not the U1 snRNP, and the catalytically
active spliceosome, or A complex, containing the U2, U6, and U5 snRNPs. Northern blot analysis and affinity
purification of the snu17D spliceosome showed that it contains the U1, U2, U6, U5, and U4 snRNPs. The un-
expected stabilization of the U1 snRNP and the lack of dissociation of the U4 snRNP suggest that loss of
Snu17p inhibits the progression of spliceosome assembly prior to U1 snRNP release and after [U4/U6.U5]
tri-snRNP addition.
Nuclear pre-mRNA splicing occurs via a two-step transes-
terification reaction that is catalyzed by a multicomponent
complex termed the spliceosome (25). The spliceosome is built
by the ordered association of the U1, U2, U4, U5, and U6
small nuclear ribonucleoprotein particles (snRNPs) and extrin-
sic protein factors with the pre-mRNA (reviewed in references
19, 25, 40, and 46). Each individual snRNP contains a unique
set of particle-specific proteins and seven common Sm pro-
teins, while the U6 snRNP contains a unique set of Sm-like
(Lsm) proteins. The U5, U4, and U6 snRNPs form a trimeric
complex in which the U4 and U6 snRNAs are extensively base
paired.
The spliceosome is a highly dynamic molecular machine,
forming anew on each pre-mRNA substrate in an ordered
manner (4, 40). First, the U1 snRNP binds the pre-mRNA by
interacting with the 59 splice site (34, 38), leading to the for-
mation of commitment complexes in yeast (33, 38) and the E
complex in mammals (24). The U2 snRNP, which interacts
with the pre-mRNA branchpoint region, is then added in an
ATP-dependent step, resulting in the formation of the prespli-
ceosome (reviewed in reference 25). Finally, U4, U5, and U6
snRNPs, preassembled in a single particle, join the prespliceo-
some to form the mature spliceosome, in which the pre-mRNA
splicing reaction occurs. Several rearrangements then take
place that activate the spliceosome for the two catalytic steps of
splicing. For example, U1 and U4 are destabilized and the
spliceosome is activated for catalysis (4). The first splicing
reaction creates two intermediates, a cleaved upstream exon
and an intron-downstream exon in a branched “lariat” config-
uration. The second splicing reaction results in the ligation of
the exons and excision of the lariat-intron. The spliceosome
then disassembles, and the products of the reaction are re-
leased.
As mentioned above, at the molecular level the assembly
pathway involves rearrangements of RNA-RNA interactions,
many of which must be disrupted to allow the formation of
others (27, 40). After the 59 splice site is recognized by U1
through base pairing (37, 39, 49), this interaction must be
replaced by a mutually exclusive interaction with U6 (15, 18,
21, 36, 44). Similarly, the base-pairing interaction between U4
and U6 must be disrupted to allow the U2-U6 interaction,
which comprises a major element of the spliceosome’s catalytic
core (23). These rearrangements are thought to be critical for
activating the spliceosome for the catalytic steps of splicing.
Notably, the DEAD-box ATPase Prp28p was identified as a
potential mediator of the U1-to-U6 switch, perhaps by unwind-
ing either the U1-59 splice site duplex or the U4-U6 duplex
(41). In addition, a mutation in U4 snRNA, which blocks
U4-U6 unwinding as well as U1 release, can be suppressed by
a specific mutation in the U5 snRNP protein Prp8p (20).
These and other data indicate that snRNP proteins play a
key role in triggering the activation of the spliceosome and in
spliceosome assembly (8). Some of these proteins were iden-
tified genetically in yeast, while others were characterized bio-
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chemically in various systems. Using these tools, the yeast U1
snRNP and the [U4/U5.U6] tri-snRNP recently have been ex-
tensively characterized (11, 12, 26, 32, 42). In contrast, our
knowledge of the yeast U2 snRNP is less comprehensive, since
a distinct U2 snRNP equivalent to the human U2 snRNP could
only be partially purified from yeast (6). This led to the iden-
tification of a novel essential splicing factor, Rse1p/Snu154p,
the yeast ortholog of the human protein SAP130, which is one
of the subunits of the heteromeric U2 snRNP-associated splic-
ing factor SF3b (6, 11). The human U2 snRNP contains nine
characterized specific proteins besides the seven common Sm
proteins (2). Sequence analysis revealed that homologs of all
these proteins exist in yeast (5, 35, 43). Yib9p and Lea1p are
the orthologs of metazoan U2B0 and U2A9, respectively (5,
43). Cus2p is also a yeast U2 snRNP-associated protein but
apparently does not have a human counterpart that associates
with the human U2 snRNP (48). Based on several criteria, the
PRP9, PRP11, and PRP21 gene products are homologs of the
mammalian SF3a subunits; Hsh49p, Cus1p, and ySAP155, to-
gether with Rse1p (Snu154p), are homologs of the mammalian
SF3b subunits (14, 28, 30, 31, 45, 47).
Although considerable progress has been made in identify-
ing the critical RNA-RNA and RNA-protein interactions re-
quired for splicing, little is understood about the factors me-
diating the structural dynamics. While characterizing the yeast
[U4/U6.U5] tri-snRNP proteins, we identified several U1 and
U2 snRNP-specific proteins in our tri-snRNP preparations,
which probably were due to the small amounts of copurifying
U1 and U2 snRNPs (11). Here, we describe the characteriza-
tion of one of these proteins with a predicted molecular mass
of 17 kDa encoded by open reading frame YIR005w. This
protein, named Snu17p, contains an RNA recognition motif
(RRM). We show that Snu17p is specifically associated with
the U2 snRNP and is an intrinsic component of prespliceo-
somes and spliceosomes, even after the first catalytic step of
splicing has occurred. Deletion of the SNU17 gene leads to a
slow-growth phenotype and to a splicing defect in vivo and in
vitro. We demonstrate that the in vitro splicing defect is due to
the lack of Snu17p since it can be specifically reversed by ad-
dition of recombinant protein. Analysis of spliceosomal com-
plexes shows that in extracts lacking Snu17p an unusual com-
plex accumulates that contains U1, U2, U4, U5, and U6
snRNPs. Thus, deletion of Snu17p traps the prespliceosome
and allows the [U4/U6.U5] tri-snRNP to bind to this interme-
diate. However, progression to a more mature form of the
spliceosome is inhibited.
MATERIALS AND METHODS
Yeast strains and plasmids. A yeast strain expressing the Snu17p protein with
a C-terminal protein A tag was created using a PCR-based strategy as previously
described (11, 29). The SNU17 39 untranslated region (39-UTR) was amplified
from yeast genomic DNA using oligonucleotides B1 and B2. This construct was
ligated to the protA-TRP1 cassette from plasmid pBS1173, cleaved with XhoI,
and filled in with Klenow fragment. The DNA cassette encoding the protein A
tag and carrying the TRP1 marker gene and the SNU17 39-UTR was then
amplified by PCR from the ligation mixture using oligonucleotide B3, which is
homologous to the 39-end of the SNU17 coding region and eliminates the stop
codon, and oligonucleotide B2. The PCR product was transformed into strain
TR2 (MATa trp1-D1 his3-D ura3-52 lys2-801 ade2-101) to give rise to strain
AGY9.
The SNU17 gene was deleted by a PCR-based strategy, replacing the entire
coding region with the HIS3-marker gene. First, the 59- and 39-UTRs were
amplified from yeast genomic DNA using primers SNU17 59-up and SNU17
59-low as well as SNU17 39-up and SNU17 39-low. The HIS3 marker gene was
amplified using primers HIS3 up BsrGI and HIS3 low AatII, which are homol-
ogous to the 59-UTR and 39-UTR of SNU17, respectively. The 59-UTR product
was then fused by PCR to the HIS3 gene using primers SNU17 59-up and HIS3
low AatII. The resulting product was purified and then fused by PCR to the
39-UTR product using primers SNU17 59-up and SNU17 39-low. The final 59-
UTR–HIS3–39-UTR cassette was then transformed into strain TR1. Integrants
were selected on medium lacking histidine, giving rise to strain AGY17. These
cells were then sporulated, and tetrads were dissected. All four spores were
viable, although the two spores containing the HIS3 marker grew slower. Thus,
a haploid snu17D strain was isolated (AGY21) (trp1-D1 his3-D ura3-52 lys2-801
ade2-101 snu17D::HIS3).
Expression and purification of GST-Snu17p fusion protein. The coding region
of SNU17 was amplified by PCR from yeast genomic DNA using oligonucleo-
tides SNU17 up BamHI and SNU17 low XhoI. The PCR product was cut with
BamHI and XhoI and ligated into vector pGEX-4T1 (Amersham-Pharmacia)
between the respective restriction sites. This plasmid was transformed into Esch-
erichia coli strain BL21. Glutathione S-transferase (GST)–Snu17p fusion protein
was overexpressed and purified as specified by the manufacturer (Amersham-
Pharmacia). It was subsequently dialyzed against buffer D150 (20 mM HEPES-
KOH [pH 7.9], 150 mM KCl, 8% glycerol, 0.5 mM phenylmethylsulfonyl fluo-
ride, 0.5 mM dithiothreitol) and stored in small aliquots at 280°C.
Immunoprecipitation, Northern analysis, and primer extension. Splicing ex-
tracts were prepared from strain AGY9, essentially as described previously (22).
A 20-ml volume of immunoglobulin G (IgG)-agarose (Sigma) was washed with
buffer NET-2 75 (50 mM Tris-HCl [pH 7.5], 75 mM NaCl, 0.05% NP-40) and
used to precipitate Snu17p-ProtA from 50 ml of extract for 1.5 h at 4°C. The
beads were then washed three times with 1.5 ml of NET-2 75. Parallel precipi-
tations were washed with NET-2 buffers containing 150, 225, 300, or 375 mM
NaCl. As control, extract from the isogenic strain TR2 was precipitated with IgG
beads. The beads were then incubated with proteinase K for 15 min at 37°C. The
copreciptated snRNAs were subsequently extracted with phenol-chloroform-
isoamyl alcohol (50:49:1) and separated by electrophoresis on a denaturing gel
containing 6 M urea and 8% polyacrylamide. After the gels were blotted to a
nylon membrane (Quiagen), which was UV irradiated for 3 min, Northern
analysis with uniformly radiolabeled DNA probes specific for the U1, U2, U4,
U5, and U6 snRNAs was performed. In vivo accumulation of unspliced pre-U3A
and pre-U3B RNA transcripts was assayed by primer extension, as described
previously (11).
In vitro splicing complementation with recombinant Snu17p, precipitation of
splicing-reaction products, nondenaturing gels, and affinity purification of spli-
ceosomes. Splicing reactions were performed as described previously (22), gen-
erally using actin pre-mRNA transcribed in the presence of [a-32P]UTP. When
splicing extracts were complemented with recombinant GST-Snu17p protein, 50
ng of protein (1.2 pmol) in 0.5 ml of buffer D150 per 5 ml of reaction mixture was
used. As a control, only 0.5 ml of buffer D150 was added.
Precipitation of Snu17p-protA and associated pre-mRNA or derived mRNA
species from in vitro splicing-reaction mixtures was performed as previously
described (11), using the AGY9 extract and radiolabeled transcripts of actin or
U3 pre-mRNA. A 30-ml volume of extract was incubated with 150,000 cpm of
32P-labeled pre-mRNA (specific activity, 10,000 cpm/fmol) for 40 min under
splicing conditions. We kept 1/15 of the mixture for analysis of the splicing
reaction, while the remaining splicing mixture was precipitated using 20 ml of
IgG-agarose (Sigma) in NET-2 150 buffer for 1.5 h at 4°C. Coprecipitated pre-
mRNA and splicing products were extracted from the washed IgG-agarose beads
and analyzed by denaturing gel electrophoresis followed by autoradiography.
Nondenaturing gel electrophoresis was performed as described previously (7),
except that the EDTA concentration used to block spliceosome assembly in A1
was 8 mM instead of 5 mM. Oligonucleotide d1, used to destroy U6 snRNA, is
described in reference 10. For affinity purification of spliceosomes, actin pre-
mRNA was transcribed in the presence of biotin-16-UTP (Boehringer) with
UTP/biotin-16-UTP ratio of 20:1. Standard splicing-reaction mixtures (125 ml)
containing 50 ml extract and 640 fmol of biotinylated actin pre-mRNA were
incubated for 20 min at 23°C, treated with 2 mg of heparin per ml of extract, and
then sedimented on a 2.4-ml 10 to 30% glycerol gradient in buffer D containing
100 mM KCl. The gradients were run for 3 h at 55,000 rpm in a Beckman TL-100
ultracentrifuge. After fractionation of the gradient into 15 fractions of 160 ml,
four-fifths of each fraction was used for affinity purification by addition of 15 ml
of streptavidin agarose in 450 ml of NET-2 buffer containing 100 mM NaCl, for
1.5 h at 4°C. The precipitates were washed extensively with NET-2 100, and
RNAs were extracted from the beads and analysed by Northern blot analysis.
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Oligonucleotides used in this work. The following oligonucleotides were used:
B1 (59-ATAATTTTTTCTTTCATC-39), B2 (59-GCTACTGCCGTGCAAAAA-
39), B3 (59-AAGAACAATGCTGAGAAACTCATTTTGGCTAAAAAGGAC
CAACCACCTCCGCTGGAGCTCAAAAC-39), SNU17 59-up (59-GAAGAGC
TGAAGCAATGA-39), SNU17 59-low (59-TTCTAGATGTACACCGCCGAAT
TGCACGCTGCACTT-39), SNU17 39-up (59-TCGATACGACGTCCCGCCGA
ACAATGCTGAGAAACTC-39), SNU17 39-low (59-AGCTTTAGCTGGAGGC
GT-39), HIS3 up BsrGI (59-GGCGGTGTACATCTAGAAAGAGCTTGGTG-
39), HIS3 low AatII (59-GGCGGGACGTCGTATCGAGTTCAAGAGAA-39),
SNU17 up BamHI (59-GGCGGGGATCCAACAAAATTCAGCAAATC-39),
and SNU17 low XhoI (59-GGCGGCTCGAGTTAATTTGGTTGGTCCTT-39).
RESULTS
Snu17p contains an RRM. We have recently isolated the
yeast [U4/U6.U5] tri-snRNP using two affinity chromatography
steps (11). Subsequently, by glycerol gradient centrifugation we
could partially separate the [U4/U6.U5] tri-snRNP from con-
taminating U1 and U2 snRNPs. Thirty-four protein bands with
molecular masses ranging from ca. 10 to 200 kDa and comi-
grating with the U4, U5, and U6 snRNAs were identified.
Peptides generated proteolytically from these bands were an-
alyzed by mass spectrometry and database searching. Twenty-
eight distinct proteins were shown to be specifically associated
with the [U4/U6.U5] tri-snRNP. Two of the remaining proteins
were identified as U2-specific proteins, Hsh49p (14) and Rse1p
(6, 11). Both are subunits of the heteromeric, U2 snRNP-
associated splicing factor SF3b. In addition to the proteins of
the [U4/U6.U5] tri-snRNP and these two U2 snRNP proteins,
we identified a novel protein which we named Snu17p. This pro-
tein contains an RNA recognition motif or RRM (Fig. 1) (3).
A BLAST search in the protein database (1) with Snu17p
identified homologous proteins, which could potentially be
orthologs, in Drosophila melanogaster (accession number
AAP53845), Arabidopsis thaliana (AL133292), Caenorhabditis
elegans (U23450), Schizosaccharomyces pombe (AL033388), Plas-
modium falciparum (AL034559), and Homo sapiens (AF078865);
these proteins exhibited a high degree of homology to Snu17p
(50% identity in a region spanning the first 120 amino acids
[Fig. 1A and data not shown]). All of these proteins share an
RRM which spans positions 21 to 109 of Snu17p (3) (Fig. 1A
and data not shown). All of these homologs, with the exception
of the Drosophila protein, are much longer at their C terminus
than is Snu17p. However, homology to Snu17p is not confined
solely to their RRMs, since additional short regions of homol-
ogy were also detected in the flanking N-terminal and C-ter-
minal regions (Fig. 1A). Since all of these proteins had align-
ment scores higher than 100, they may be possible orthologs of
Snu17p. Several other homologous proteins with lower align-
ment scores (ca. 60 to 40) emerged during the search, but since
their homology to Snu17p is restricted exclusively to their
RRMs, they are most probably putative RNA binding proteins,
functionally unrelated to Snu17p. A TBLASTN search in the
human expressed sequence tag (EST) database revealed that
beside the ESTs encoding the human protein shown in Fig. 1A
(alignment score, 124), several more ESTs exist that encode a
product homologous to Snu17p. Interestingly, among these is
EST AA314241 (alignment score, 53), which encodes a 14-kDa
protein, named p14, that is associated with both U2 and U11-
U12 snRNPs (C. L. Will, C. Schneider, A. M. MacMillan, N.
Katopodis, G. Neubauer, M. Wilm, R. Lu¨hrmann, and C. C.
Query, submitted for publication). Although this protein shows
only 36% identity and 53% similarity to Snu17p in a region
spanning 96 amino acids from positions 30 to 125, it is similar
in length (Fig. 1B). Since similar length may be an important
parameter to conclude whether two proteins are genuine or-
thologs and, most importantly, considering that there is exper-
imental evidence that p14 is associated with U2 snRNPs in
HeLa cells (Will et al., submitted), p14, and not the protein
shown in Fig. 1A, may be the bona fide human counterpart of
Snu17p.
Snu17p is a U2 snRNP protein. To investigate whether
Snu17p is stably associated with one of the snRNP particles, we
added a cassette coding for two IgG binding units of Staphy-
lococcus aureus protein A (29) downstream of the SNU17 cod-
ing sequence in vivo. Splicing extracts were prepared and used
in immunoprecipitation experiments. Immunoprecipitation re-
actions were performed with extracts containing protein A-
tagged Snu17p (Snu17p-protA) and control extracts obtained
from an isogenic strain containing untagged protein and then
washed at increasing salt concentrations. Subsequently, the
FIG. 1. Sequence alignment of S. cerevisiae Snu17p with homologous proteins. (A) Snu17p is aligned with a homolog from H. sapiens
(AF078865). Identical residues are boxed in black, and similar residues are boxed in grey. The amino acid positions are indicated by numbers. (B)
Snu17p is aligned with an H. sapiens cDNA product from EST186153 AA314241. The position of the Snu17p RRM is indicated above the
sequences by a shaded box.
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precipitated snRNAs were identified by Northern blot analysis.
The U2 snRNA coprecipitated with Snu17p in a specific man-
ner (Fig. 2). The amount of coprecipitated U2 snRNP only
slightly decreased, increasing the NaCl concentration from 75
to 375 mM KCl. Only background U1 snRNA was coprecipi-
tated (Fig. 2, compare with the control extract [No tag] and
with the total RNA [lane 11]). Also, very small amounts of
U5L, U5S, U4, and U6 snRNAs were coprecipitated at all salt
concentrations tested. This is most probably due to the inter-
action of the U2 snRNP with the tri-snRNP (11, 16). This
experiment demonstrates that Snu17p is stably and specifically
associated with the U2 snRNP even at high salt concentrations.
Therefore, we have named this protein Snu17p, for the “snurp”
protein of 17 kDa.
Snu17p is associated with the spliceosome during splicing in
vitro. To learn more about Snu17p interactions, we investi-
gated whether Snu17p is associated with the spliceosome dur-
ing the course of a splicing reaction in vitro. We therefore used
the Snu17p-protA extract and the untagged control extract
to perform in vitro splicing with labeled actin and U3 pre-
mRNAs (Fig. 3). Aliquots of the splicing-reaction mixtures
were removed after 20 and 40 min and analyzed for splicing
activity. After 40 min the remaining splicing-reaction mixture
was immunoprecipitated using IgG-agarose beads (Fig. 3). Sig-
nificant amounts of the pre-mRNA were coprecipitated from
the extracts containing Snu17p-protA (Fig. 3, lanes 6 and 12)
but not from the control extract containing untagged Snu17p
(lanes 3 and 9). Using either of the two precursors, significant
amounts of the lariat-exon 2 intermediate were also coprecipi-
tated (lanes 6 and 12). This suggests that Snu17p, as part of the
U2 snRNP, associates with the pre-mRNA in the prespliceo-
some. Moreover, Snu17p is also part of the catalytically active
spliceosome, since it is associated with the lariat-exon 2 inter-
mediate, which is formed during the first step of the pre-
mRNA splicing reaction (lanes 6 and 12). Since Snu17p asso-
ciates with spliceosomes assembled on at least two precursors,
actin and U3 pre-mRNAs, this indicates that it is a general
splicing factor.
Deletion of SNU17 confers a slow-growth phenotype. In view
of the results obtained above, we were interested in determin-
ing whether Snu17p is essential for cell viability. We performed
a genetic knockout of the SNU17 gene in a diploid strain by
replacing its coding sequence with the HIS3 marker gene.
After sporulation and tetrad dissection of this strain at 25°C,
we observed that all four spores were viable, demonstrating
that this gene is not essential for vegetative cell growth (data
not shown). However, we noticed that two spores in each
tetrad grew slower (data not shown). These spores carried
the HIS3 marker, indicating that the strains lacking SNU17
(snu17D) were viable but impaired for vegetative growth at
25°C. We then isolated haploid cells carrying snu17D and
tested their growth ability at 17, 30, and 37°C. The slow-growth
phenotype of these cells was not apparently exacerbated by
increasing or lowering the temperature, compared to that of an
isogenic wild-type strain grown at the same temperature. At
each temperature, the snu17D::HIS3 cells grew about 1.3-fold
FIG. 2. Snu17p is a yeast U2 snRNP protein. DNA coding for a
tandem repeat of S. aureus protein A was fused 39 to SNU17. Extracts
(50 ml) from the resulting strain (Snu17p-tag), as well as from the
parental wild-type strain (No tag), were immunoprecipitated using
IgG-agarose and then washed at various NaCl concentrations, as in-
dicated above the lanes. The snRNA content of the precipitates was
assayed by Northern blot analysis (snRNAs are indicated). Total refers
to the total RNAs from 4 ml of extract (8% of the total input) before
immunoprecipitation.
FIG. 3. Pre-mRNA and the lariat-intron intermediate coprecipi-
tate with Snu17p under in vitro splicing conditions. Splicing reactions
using either extracts containing Snu17p without tag (lanes 1 to 3 and 7
to 9) or protein-A tagged Snu17p (lanes 4 to 6 and 10 to 12) were
incubated under splicing conditions with 32P-labeled actin pre-mRNA
(lanes 1 to 6) or U3 pre-mRNA (lanes 7 to 12) for 20 or 40 min at 25°C.
Then 93% of the 40-min reaction volume was precipitated with IgG
agarose. For each time point, 7% of the total reaction mixtures (lanes
1, 2, 4, 5, 7, 8, 10, and 11) and the precipitate from the remaining 93%
of the reaction mixtures (IP; lanes 3, 6, 9 and 12) were assayed for the
presence of pre-mRNA, splicing intermediates, and products. Indi-
cated on the left and on the right are the identities of the labeled RNA
species: intron-lariat-exon 2 intermediate, excised lariat-intron, pre-
mRNA, mature mRNA, and cleaved exon 1 intermediate.
3040 GOTTSCHALK ET AL. MOL. CELL. BIOL.
 o
n
 February 22, 2016 by M










slower than the wild-type cells did (data not shown). An iden-
tical phenotype was observed by Entian et al., who systemati-
cally studied S. cerevisiae genes of unknown function (9). After
deletion of YIR005w ORF, which corresponds to SNU17, they
observed a reduced growth rate on glucose and on several oth-
er fermentable carbon sources and alterations in the cell cycle,
with an increased proportion of cells with 1n DNA content
compared to the wild type (9). Although Snu17p is not essen-
tial for vegetative cell growth, we have shown that it is present
in the spliceosome during the course of the splicing reaction
at least prior to the second step of splicing (Fig. 3; also see
above). It was therefore interesting to determine whether the
deletion of SNU17 had an effect on splicing in vivo and in vitro.
Deletion of SNU17 leads to a pre-mRNA splicing defect in
vivo and to inhibition of splicing prior to the first catalytic step
in vitro. We determined whether SNU17 is required for pre-
mRNA splicing in vivo by measuring the levels of unspliced
U3A and U3B transcripts in cells grown at 25 and 37°C, re-
spectively. Figure 4A shows the results of a primer extension
analysis of U3 transcripts from wild-type and snu17D cells. A
slight but higher than background accumulation of unspliced
pre-U3A and pre-U3B transcripts was found (Fig. 4A, lane 3)
(snu17D), in comparison to the parental control (lane 1). The
splicing defect was exacerbated after the cells were switched
for 2 and 4 h from 25 to 37°C (compare lane 2 with lanes 4 and
5). Thus, although deletion of SNU17 does not lead to a dis-
cernible temperature-sensitive phenotype, it does cause a splic-
ing defect which is intensified by increasing the temperature.
To study whether the deletion of SNU17 has an influence on
the splicing reaction, we prepared splicing extract from the
snu17D strain and compared its ability to carry out splicing in
vitro with that of a wild-type extract. We performed in vitro
splicing reactions at 25°C and withdrew aliquots of the reaction
mixtures at 1, 5, 15, and 25 min. (Figure 4B). The deletion of
SNU17 led to a dramatic decrease in splicing prior to the first
step (Fig. 4B, compare lanes 9 to 12 with lanes 1 to 4). To
determine whether this reduction was due specifically to the
lack of Snu17p, we tested whether the splicing activity of the
extract lacking Snu17p could be restored by adding recombi-
nant GST-Snu17p to the splicing-reaction mixture. We there-
fore performed splicing in the presence of GST-Snu17p, which
was preincubated with the wild-type and snu17D extracts prior
to the addition of the pre-mRNA. With the snu17D extract, the
addition of recombinant Snu17p efficiently reversed the splic-
ing defect (Fig. 4B, lanes 13 to 16). Addition of recombinant
Snu17p to the wild-type extract did not have any detectable
effect (lanes 5 to 8). We conclude that the in vitro splicing de-
fect is due to the specific loss of Snu17p and not to an indirect
effect, such as loss of another factor in addition to Snu17p or
instability and degradation of the U2 snRNA.
Deletion of SNU17 leads to accumulation of an unusual
spliceosomal complex. To investigate the step of spliceosome
assembly at which Snu17p acts, we separated spliceosomal
complexes by electrophoresis on nondenaturing polyacryl-
amide gels. Spliceosomal complexes were assembled at 30°C
on 32P-labeled actin pre-mRNA, using wild-type and snu17D
FIG. 4. Snu17p is required for efficient splicing in vivo and in vitro. (A) RNA was extracted from wild-type (WT) and snu17D cells grown at
25°C (lanes 1 and 3) and after the switch to 37°C for 2 h (lane 4) and 4 h (lanes 2 and 5). Primer extension analysis was performed to measure
the levels of unspliced pre-U3A and pre-U3B transcripts, indicated on the right. (B) Splicing reactions were performed at 25°C using the wild-type
(lanes 1 to 8) and snu17D (lanes 9 to 16) extracts for the time indicated above each lane. To restore splicing, 1.2 pmol of recombinant GST-Snu17p
was added to the reaction mixtures prior to addition of the actin precursor (lanes 5 to 8 and 13 to 16). Indicated on the left is the identity of the
32P-labeled RNA species (from top to bottom): intron-lariat-exon 2 intermediate, excised lariat-intron, pre-mRNA, mature mRNA, and cleaved
exon 1 intermediate.
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extracts (Fig. 5A). Interestingly, the lack of SNU17 led to the
formation of a single, slowly migrating complex, which we
named complex X (Fig. 5A, lanes 5 and 6). This complex had
already accumulated after 10 min of incubation. Under the
same conditions, at least two distinct complexes were formed
in wild-type extracts: the B and A complexes. A third complex,
A1, was usually less abundant (lanes 2 and 3). Previous analysis
of the B complex (7) showed that it contains the U2 snRNP but
not the U1 snRNP, which is only loosely bound and is lost from
complex B due to heparin treatment (7, 17). The A complex
(named A2-1 and A2-2 at early and later incubation times,
respectively) and the A1 complex usually contain the U2 and
[U4/U6.U5] snRNPs or the U2, U6, and U5 snRNPs, respec-
tively (Fig. 5B gives a summary).
We noticed that complex X exhibits migration behavior sim-
ilar to that of complex A1. To analyze whether the deletion of
SNU17 leads to accumulation of complex A1, we studied the
RNA composition of complex X by Northern blot analysis
(Fig. 6). Spliceosomal complexes were assembled on unlabeled
actin precursor at 30°C. After 0, 5, and 20 min, aliquots of the
reaction mixture were incubated on ice and a solution contain-
ing heparin was added. The complexes were separated on a
native gel, blotted, and then hybridized with probes for the
actin precursor and subsequently for the U1, U2, U4, U5, and
U6 snRNAs (Fig. 6a to f). Hybridization with the actin and the
U2 probes revealed the position and composition of complexes
B, A, and A1 in the wild-type extract (Fig. 6a and b, lanes 2 and
3). To increase the signal of the A1 complex in this experiment,
we added EDTA to the splicing-reaction mixture. As shown
previously (7), addition of EDTA blocked spliceosome assem-
bly, leading to accumulation of complex A1, which, as antici-
pated, contained the U2 snRNP but not the U1 snRNP (Fig.
6b and c, lanes 8 and 9, respectively). Surprisingly, analysis of
complex X showed that it contained not only the U2 snRNP
but also the U1 snRNP (Fig. 6b and c, lanes 11 and 12, re-
spectively). In addition, we noticed that in extracts deficient in
Snu17p the U2 snRNP (U2* snRNP) ran aberrantly (Fig. 6b,
lanes 10 to 15), forming a diffuse, slower-migrating band (com-
pare with the wild-type U2 snRNP), indicating that its struc-
ture is somehow compromised.
To determine whether the [U4/U6.U5] tri-snRNP is part of
complex X, the blot was hybridized with the U6, U5, and U4
probes. U6 and U5 were identified in the wild-type A and A1
complexes (Fig. 6d and e, lanes 2 and 3 and lanes 8 and 9). As
expected, U4 was identified only in the A but not in the A1
complexes (Fig. 6f, lanes 2 and 3 and lanes 8 and 9). As shown
in Fig. 6d to f, lanes 11 and 12, complex X also contained the
U6, U5, and U4 snRNPs. The controls show that in the wild-
type extract, deletion of U6 by oligonucleotide-directed RNase
H cleavage blocked the binding of the tri-snRNP and led to the
accumulation of complex B, which, as expected, contained the
substrate and the U2 snRNP but not the U1 snRNP (Fig. 6a to
c, lanes 5 and 6). Digestion of U6 in wild-type extracts led to
nearly complete disappearance of the U6, U5, and U4 signals
(Fig. 6d to f, lanes 5 and 6), suggesting that, normally, deletion
of U6 blocks the entry of the [U4/U6.U5] tri-snRNP. When the
snu17D extract was treated to destroy U6, the latter completely
disappeared from complex X (Fig. 6d, lanes 14 and 15). How-
ever, U5 still appeared to be present (Fig. 6e, lanes 14 and 15).
Since the U5 and U4 snRNP were never clearly detected by
this method, as an independent assay to support the existence
of the [U4/U6.U5] tri-snRNP in complex X, we have purified
spliceosomes that were assembled onto biotinylated pre-
mRNA in vitro. Splicing-reaction mixtures were incubated
with biotinylated unlabeled substrate using either wild-type or
snu17D extracts (Fig. 7). Spliceosomal complexes were then
fractionated by centrifugation on a 10 to 30% glycerol gradi-
ent, and their RNA composition was analyzed following pre-
cipitation with streptavidin beads (Fig. 7, lanes 2 and 4). The
snRNAs present in gradient-fractionated spliceosomes precip-
itated with streptavidin (the ca. 40S region of the gradient
[lanes 2 and 4]), as well as the input of the total snRNPs before
incubation and fractionation, were assayed by Northern blot
analysis (lanes 1 and 3). The snu17D spliceosome contained
large amounts of U1, U2, and U5 but smaller amounts of U4
and U6 snRNAs (lane 4). Note that the U4 and U6 snRNA
FIG. 5. Deletion of SNU17 leads to accumulation of an unusual
spliceosomal complex. (A) Spliceosomes were assembled on a 32P-
labeled actin pre-mRNA by incubation in mock-treated wild-type
(WT) and snu17D extracts at 30°C. Aliquots were withdrawn after 0,
10, and 20 min and treated with a buffer containing heparin. Nonde-
naturing gels were run for 5 h (7). The identities of the complexes are
indicated on the left. The unusual, slow-migrating complex seen only in
snu17D extracts is designated complex X. (B) Yeast spliceosome as-
sembly, as in reference 7. RNase H-mediated digestion of U6 snRNA
(DU6) blocks spliceosome assembly at the B complex stage, whereas
addition of 5 to 8 mM EDTA blocks spliceosome assembly at the A1
complex stage.
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were in general not well represented in both extracts. One
reason may be that the U6 and U4 probes had a lower specific
activity than the U1, U2, and U5 probes in some of our exper-
iments. The snRNA composition of the wild-type spliceosome
indicates that it contains in proportion slightly less U2 but
much less U1 than the snu17D spliceosome (Fig. 7, compare
lane 2 with lane 4). Importantly, the wild-type spliceosome has
released U4, since the U4 snRNA is not detectable (lane 2).
However, the snu17D spliceosome does contain detectable lev-
els of U4 (lane 4). The controls show that the total snRNA
contents of the wild-type and snu17D extracts before spliceo-
some assembly, gradient fractionation, and affinity purification
are practically indistinguishable, including the lower levels of
the U4 and U6 snRNAs (compare lane 1 with lane 3). In
summary, the conclusion that complex X, the snu17D spliceo-
some, contains all of the snRNPs is supported and strength-
ened by this independent experiment. From the combination
of these experiments, we conclude that complex X contains the
U2, U6, U5, and U4 snRNPs and, unusually, a U1 snRNP that
is stably associated with the complex even after treatment with
heparin. The unexpected stabilization of the U1 snRNP and
the lack of release of the U4 snRNP in spliceosomes lacking
Snu17p suggest that deletion of Snu17p inhibits the progres-
sion of spliceosome assembly prior to U1 snRNP release and
after [U4/U6.U5] tri-snRNP addition.
DISCUSSION
In this work, we have presented the isolation and character-
ization of a novel yeast U2 snRNP protein, Snu17p. Using
affinity purification experiments performed during the course
of the splicing reaction, we showed that Snu17p coprecipitates
unspliced precursor and spliced lariat-exon 2 intermediate.
This demonstrates that Snu17p is a component of the spliceo-
some at least until prior to the second catalytic step of splicing.
In addition, extracts prepared from the knockout strain exhib-
ited a dramatic reduction in splicing prior to the first catalytic
step. Notably, the splicing inhibition was reversed by addition
of recombinant Snu17p (Fig. 4B). This indicates that, similar to
the in vivo situation, Snu17p is required in vitro to sustain
efficient splicing and that the splicing reduction is directly due
to the lack of Snu17p. To exclude the possibility that deletion
FIG. 6. RNA composition of complex X. Spliceosomes were assembled on unlabeled actin pre-mRNA. Splicing reactions were performed using
wild-type (WT) or snu17D extracts at 30°C, either mock treated, treated to destroy U6, or treated with 8 mM EDTA as indicated above each lane.
Aliquots were withdrawn after 0, 5, and 20 min, blocked on ice, and treated with a buffer containing heparin. Nondenaturing gels were run, blotted,
and sequentially hybridized with probes for the actin precursor (Actin) (a) and subsequently for the U2 (b), U1 (c), U6 (d), U5 (e), and U4 (f)
snRNAs. The complexes are indicated on the left. Complex X is an unusual slow-migrating complex seen only in snu17D extracts.
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of Snu17p inhibits splicing due to an indirect effect, such as
reduced levels of the U2 snRNA, we have analyzed the U2
snRNP lacking Snu17p by glycerol gradient centrifugation fol-
lowed by Northern blot analysis. These experiments showed
that the level of U2 snRNPs appears normal, if not increased,
in the knockout strain (data not shown). In addition, the sed-
imentation behavior of the mutant U2 snRNP is indistinguish-
able from that of the wild type (data not shown). An alternative
but highly likely indirect effect which would explain the rever-
sion of the splicing defect after addition of recombinant Snu17p is
an impaired structure or conformation of the U2 snRNP lack-
ing Snu17p (Fig. 6b, U2* snRNP). A partially inactive U2 snRNP
due to the presence of an altered structure could be reversed
to normal after the addition of recombinant Snu17p, and as a
result, pre-mRNA splicing may also be restored. This would
explain why the deletion of Snu17p has a less drastic effect in
vivo than in vitro. In vivo, an aberrant conformation of the U2
snRNP due to the lack of Snu17p may be stabilized and com-
pensated by other factors which are found in an in vivo envi-
ronment (physiological salt, pH, temperature, etc.). In vitro,
the conformation of the weakened U2* snRNP may not be
sufficiently stabilized to support a splicing reaction under the
limiting assay conditions used in the test tube.
When the products of a splicing reaction performed in
snu17D extract are analyzed on a non-denaturing gel, the spli-
ceosome runs as a single slowly migrating complex, complex X,
which contains the U2, U6, U5, and U4 snRNPs and a heparin-
resistant U1 snRNP. A possible explanation for the formation
of complex X is, again, misfolding of the U2 snRNP in the
absence of Snu17p. Figure 6b shows that the migration range
of the U2 snRNP lacking Snu17p (U2* snRNP) is considerably
larger than that of the wild-type U2 snRNP. It may be possible
that the unexpected stabilization of the U1 snRNP in the
spliceosome after deletion of SNU17 is due to an indirect effect
on the U2 snRNP, rather than to a direct role of Snu17p in
the U1–pre-mRNA interaction. If, for example, Snu17p con-
tributes to the correct positioning of the U2 snRNP at the
branchpoint, deletion of Snu17p may lead to an aberrant con-
formation of the U2–pre-mRNA structure which is unable
to displace U1. This aberrant U1.U2–pre-mRNA complex (a
pseudo-prespliceosome) would nevertheless be capable of in-
tegrating the [U4/U6.U5] tri-snRNP; however, further rear-
rangements would be inhibited or greatly slowed such that the
complex does not progress to a catalytic form. Whether the
aberrant conformation of the U2* snRNP is reversed to nor-
mal after the addition of recombinant Snu17p has not been
analyzed. However, addition of recombinant Snu17p to snu17D
extracts, prior to addition of pre-mRNA, efficiently reverses
the splicing defect (Fig. 4B). When the reconstitution experi-
ment with recombinant Snu17p is performed and the reaction
product is analyzed on a nondenaturing gel, complex X is
replaced, at least in part, by a faster-migrating complex, which
must be the active form of the spliceosome since splicing is
restored (Fig. 4B and data not shown). Only further experi-
ments may clarify this point.
It is interesting that the phenotype of the Snu17p deletion
strain is unique. In extracts prepared from strains lacking other
U2 proteins, like LEA1 and/or Y1B9/U2B0, spliceosome assem-
bly is blocked prior to the addition of the U2 snRNP (5). In
addition, strains lacking LEA1 and/or Y1B9/U2B0 contain re-
duced levels of U2 snRNA, while the U2 snRNA present in
extracts lacking Snu17p seems to be even more abundant than
the U2 snRNA found in the wild type (Fig. 6b). Since we used
the same amounts of wild-type and snu17D extracts in our
experiments (ca. 25 mg of proteins/2 ml of extract), we can
conclude that the levels of U2 snRNP are even increased upon
deletion of SNU17. The reason for this increase remains to be
determined.
A surprising feature of complex X is the apparent lack of
stepwise assembly. Even after a very short (5-min [Fig. 6])
incubation of pre-mRNA in snu17D extracts, only a single
complex is detected. The formation of complex X is slow,
appearing first after 2 min of incubation (data not shown). This
complex already contains the U1 and U2 snRNPs, with only
very small amounts of U4-U6 and U5 snRNPs detectable.
Most probably, it is very difficult, if not impossible, to resolve
the U1.U2 complex from the U1.U2.[U4/U6.U5] or U1.U2-
U6.U5 complexes in these low-resolution gels. Moreover, we
do not know what factors govern the mobility of these com-
plexes in electrophoresis. Likewise, the fact that complex X
does not run faster in the gel even after digestion of U6 (Fig.
6a to c, lanes 14 and 15) may also not be surprising. On diges-
tion of U6, the tri-snRNP does not enter the wild-type spli-
ceosome, and complex B, the prespliceosome containing only
the U2 snRNP, accumulates. After digestion of U6, complex X
apparently still runs in the same position. This may be because
the resulting complex contains U1 in addition to U2 and also
some U5 (Fig. 6e, lanes 14 and 15). Loss of a snRNP does not
always lead to a faster-migrating behavior of splicing com-
FIG. 7. Deletion of SNU17 inhibits the dissociation of U1 and U4
from the spliceosome. Splicing-reaction mixtures were incubated with
actin pre-mRNA that was transcribed in the presence of biotinylated
UTP to incorporate an affinity label. The reaction mixtures were in-
cubated for 20 min at 23°C. Then 5 ml was withdrawn and kept for
analysis of total RNAs (Total; lanes 1 and 3). The remaining 120 ml
was treated with heparin and then sedimented by centrifugation on a
10 to 30% glycerol gradient. rRNAs from yeast were run on a parallel
gradient as sedimentation markers. Fifteen fractions (160 ml each)
were collected, and four-fifths of each fraction was affinity purified with
streptavidin-agarose (AP 5 affinity purification of a fraction of the 40S
region of the gradient corresponding to fraction 15, the spliceosome
[lanes 2 and 4]). After extensive washing, precipitated snRNAs were
assayed by Northern blotting.
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plexes. For example, the yeast complex A2-1, which contains
U2, U4-U6, and U5 (Fig. 5B), runs faster in nondenaturing
gels than does complex A1, which contains only U2, U6, and
U5. This is presumably due to conformational changes that are
coupled with the dissociation of U4 during the transition from
the A2-1 to the A1 complex (7). We do not know which type of
conformational rearrangement occurs in complex X. However,
our results provide good evidence that the [U4/U6.U5] tri-
snRNP joins the U1.U2 complex. Although the U1 snRNP
appears to be hyperstabilized, the tri-snRNP nevertheless is
able to bind. Complex X appears to be similar to the “U1-
hyper” splicing intermediate observed by Staley and Guthrie
(41), where U1 and U2 remain bound in the spliceosome along
with U4-U6 and U5 only when the U1:59 splice site interaction
is hyperstabilized, leading to a concomitant block of U1 and
U4 dissociation. Meanwhile, Kuhn et al. showed that U4-U6
unwinding and U1 release are both inhibited by the mutant U4
snRNA U4-cs1 (20). Similar to these mutations, loss of Snu17p
traps U1 in the spliceosome, still allowing the tri-snRNP to
bind but blocking the release of U4. These data also provide
evidence that the [U4/U6.U5] tri-snRNP is bound to pre-
mRNA at the prespliceosome step of assembly. This was also
observed by Staley and Guthrie using a cold-sensitive mutant
of Prp28p, prp28-1. These authors showed that at 15°C prp28-1
extracts trapped the prespliceosome and allowed the [U4/U6.U5]
snRNP to bind, although weakly, to this intermediate (41).
Snu17p contains an RRM spanning approximately 60% of
its length. Since RRMs are found in a wide variety of proteins
across species, this complicates the search for its genuine
orthologs. In our search we found proteins homologous to
Snu17p which are evolutionarily highly conserved not only in
their central region, which contains an RRM, but also in the
N-terminal part. However, since all but one are much longer
than Snu17p in their C-terminal part, we cannot conclusively
establish, without additional experimental information, wheth-
er they are functionally related to Snu17p. The p14 protein, the
product of EST AA314241, may be the functional counterpart
of Snu17p in the human spliceosome for reasons we find very
convincing: experiments show that p14 is a human U2 snRNP-
associated protein that is also found in the U11-U12 snRNP of
the minor spliceosome (Will et al., submitted).
Since Snu17p is unequivocally a U2 snRNP protein and has
an RRM, we performed initial immunoprecipitation experi-
ments to determine whether it binds directly to the U2 snRNA.
However, we could not reproducibly show that Snu17p binds
directly to in vitro-transcribed U2 snRNA, to one of the other
spliceosomal snRNAs, or to the pre-mRNA. This suggests that
Snu17p binds the U2 snRNP via protein-protein interactions.
Considering possible pre-mRNA contacts of Snu17p, all of the
human SF3a components, as well as the SF3b subunits SAP49,
SAP145, and SAP155, cross-link to the pre-mRNA close to the
branch point (13). Although we have not analyzed whether
Snu17p cross-links to the pre-mRNA, it is worth mentioning
that in human splicing extracts, p14 can be cross-linked to the
pre-mRNA at the branch point adenosine (Will et al., submit-
ted). Since Snu17p may be functionally related to p14, it is con-
ceivable that it also directly contacts the branch point sequence.
To summarize, we have identified a novel yeast U2 snRNP
protein, Snu17p, which, despite its discernible in vitro pheno-
type, is not essential in vivo. However, its genetic deletion leads
to a slow-growth phenotype and to a pre-mRNA splicing de-
fect in vivo. Our in vitro studies suggest that Snu17p may play
a role in the maturation of the spliceosome, since extracts
lacking Snu17p accumulate an unusual splicing complex con-
taining all five snRNPs: U1, U2, U4, U5, and U6. Loss of
Snu17p, in contrast to other U2 snRNP proteins analyzed (5),
allows not only the addition of the U2 snRNP to the prespli-
ceosome but also the addition of the [U4/U6.U5] tri-snRNP,
inhibiting the progression of spliceosome assembly before U1
release and after tri-snRNP addition. This phenotype is pecu-
liar, and deletion of SNU17 can be used as a tool to isolate fully
assembled spliceosomes stalled prior to the first catalytic step
of splicing and to learn more about their protein composition.
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